MGFA is dedicated to driving research to better understand, treat and cure myasthenia gravis for good. To achieve this goal, we are committed to creating awareness about clinical trials for those with myasthenia gravis and related neuromuscular joint disorders.
If you would like your clinical trial posted to our website, please complete the Research Announcement Form and email to mgfa@myasthenia.org with “Clinical Trial Announcement” in the subject line.
Active Clinical Trials
-
A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis
-
Study of Pyridostigmine with Ondansetron in Subjects with Anti-AchR Positive Myasthenia Gravis. Active and recruiting
-
Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis (ADAPTsc). Active and recruiting
-
Efgartigimod Expanded Access for Generalized Myasthenia Gravis. Active and recruiting
-
The MINT study is a randomized, double-blind, multicenter, placebo-controlled phase 3 Study with open-label period to evaluate the efficacy and safety of inebilizumab in adults with Myasthenia Gravis. Active and recruiting
-
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis, Active and recruiting
-
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients with Generalized Myasthenia Gravis, Active and recruiting (updated December 2019)
-
A Study to Evaluate the Safety and Preliminary Efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis, Active and recruiting
-
An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Eculizumab in Pediatric Patients with Refractory Generalized Myasthenia Gravis. Active and recruiting
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis. Active/ Not Recruiting
-
RVT-1401-2002: A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of RVT- 1401 in Myasthenia Gravis Patients, Active and recruiting
-
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness, Active, Not recruiting. For more updated information, READ MORE.
-
Catalyst Pharmaceuticals Clinical Trial for Firdapse in MuSK-MG Patients, Active and recruiting
- Exercise for Stable MG, Recruiting
- Innovative measures of speech and swallowing dysfunction in Neurological Disorders (QUESST), Recruiting
-
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis, Active and recruiting
National Health Institute Clinical Trial Research Database
https://clinicaltrials.gov/ct2/results?term=myasthenia&recr=Open